CERIA (Centre for Research on Angiogenesis Inhibitors), Department of Medical Oncology, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, France.
Target Oncol. 2011 Dec;6(4):253-8. doi: 10.1007/s11523-011-0201-x. Epub 2011 Nov 17.
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents.
后部可逆性脑病综合征（PRES）是一种临床-放射学实体，可能发生在接受抗血管内皮生长因子（VEGF）药物的患者中，如贝伐珠单抗和酪氨酸激酶抑制剂。对于接受抗 VEGF 药物的患者中发生 PRES 的风险特征，人们知之甚少。我们对记录接受抗 VEGF 药物的患者发生 PRES 的报告进行了全面回顾。描述了 26 例患者，其中大多数为女性（73.1%）。几乎三分之一的患者有高血压病史。最常见的症状包括头痛、视力障碍和癫痫发作。大多数患者在 PRES 诊断时存在高血压，每次检查都可检测到蛋白尿。所有病例均采用包括控制血压在内的对症治疗，神经功能预后良好。当血压控制不佳和蛋白尿可检测到时，PRES 的风险增加。临床病程表现为对症治疗有利。PRES 是抗 VEGF 药物潜在的严重但可管理的毒性。
